Risk of drug-induced congenital defects

被引:38
作者
De Santis, M [1 ]
Straface, G [1 ]
Carducci, B [1 ]
Cavaliere, AF [1 ]
De Santis, L [1 ]
Lucchese, A [1 ]
Merola, AM [1 ]
Caruso, A [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Inst Obstet & Gynaecol, Telefono Rosso Teratol Informat Serv, I-00168 Rome, Italy
关键词
congenital malformations; pregnancy; drug induced; teratogenicity;
D O I
10.1016/j.ejogrb.2004.04.022
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Defects attributable to drug therapy represent about 1% of congenital defects of known aetiology. This means that a precautionary attitude and correct use of drugs in fertile, and especially pregnant, women is a feasible form of prevention. Drugs currently in use with proven teratogenic effect number approximately 25, but new pharmaceutical drugs are constantly in preparation. Recognition of a drug-induced teratogenic effect is a complex procedure taking into account not only experimental animal data but also experience in humans. Considering that 40% of pregnancies are not planned, it follows that any drug with known or suspected teratogenic potential must be used only under strict medical control. Also, adequate knowledge on potential teratogenicity of a drug permits modification of therapy before conception. It goes without saying that any drug should be used during pregnancy only if it is essential, and it would be prudent to use only those where adequate information is provided and prior clinical experience is available. Teratology Information Services can assist both physicians and patients when any doubt exists. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:10 / 19
页数:10
相关论文
共 186 条
  • [1] Adams J, 2000, TERATOLOGY, V62, P172
  • [2] Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn
    Alano, MA
    Ngougmna, E
    Ostrea, EM
    Konduri, GG
    [J]. PEDIATRICS, 2001, 107 (03) : 519 - 523
  • [3] HEPATIC TOXICITY OF TETRACYCLINE IN PREGNANCY
    ALLEN, ES
    BROWN, WE
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1966, 95 (01) : 12 - &
  • [4] [Anonymous], 1987, TERATOLOGY, V35, P269
  • [5] [Anonymous], 1991, TERATOLOGY, V44, P1
  • [6] [Anonymous], OBSTET GYNECOL SURV
  • [7] ANUSZEWSKA E, 1991, Polish Journal of Pharmacology and Pharmacy, V43, P129
  • [8] VERIFICATION OF THE FETAL VALPROATE SYNDROME PHENOTYPE
    ARDINGER, HH
    ATKIN, JF
    BLACKSTON, RD
    ELSAS, LJ
    CLARREN, SK
    LIVINGSTONE, S
    FLANNERY, DB
    PELLOCK, JM
    HARROD, MJ
    LAMMER, EJ
    MAJEWSKI, F
    SCHINZEL, A
    TORIELLO, HV
    HANSON, JW
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS, 1988, 29 (01): : 171 - 185
  • [9] Teratogenic effects of antiepileptic drugs: Use of an international database on malformations and drug exposure (MADRE)
    Arpino, C
    Brescianini, S
    Robert, E
    Castilla, EE
    Cocchi, G
    Cornel, MC
    de Vigan, C
    Lancaster, PAL
    Merlob, P
    Sumiyoshi, Y
    Zampino, G
    Renzi, C
    Resano, A
    Mastroiacovo, P
    [J]. EPILEPSIA, 2000, 41 (11) : 1436 - 1443
  • [10] BACHRACH LK, 1984, CAN MED ASSOC J, V130, P1264